O M.S. åîïìïëïãåßôáé...

Boy Ðáßäåò äåí îÝñù ãéáôß ãñÜöù ôçí éóôïñßá ìïõ. AðëÜ Þèåëá íá ôç ìïéñáóôþ ìáæß óáò, åðåéäÞ âëÝðù üôé ðïëý êüóìïò ëÝåé äéÜöïñá åäþ ìÝóá.

ÈõìÜìáé üôé åß÷á ðïëý õøçëü ðõñåôü ìéá åâäïìÜäá êáé äåí Ýðåöôå ìå ôßðïôá. Ôáõôü÷ñïíá ïé ëåìöáäÝíåò ìïõ ðïíïõóáíå ðáñÜ ðïëý êáé äåí ìðïñïýóá íá óçêùèþ áðü ôï êñåâÜôé ãéá 5 - 6 ìÝñåò.
¢ñ÷éóá íá áíçóõ÷þ êáé íá óêÝöôïìáé äéÜöïñá êé Ýôóé áðïöÜóéóá íá ðÜù óå ãéáôñü ãéá åîåôÜóåéò.
ÐÞãá Ýíá ðñùß óôï íïóïêïìåßï ðïõ Ý÷ù ãíùóôïýò ãéáôñïýò ïéêïãåíåéáêÜ.
Åêåß óêÝöôçêá üôé äåí ðñÝðåé íá ðÜù óå áõôïýò êé Ýôóé ðÞãá óå Ýíá åîùôåñéêü éáôñåßï. ÌðÞêá ìÝóá êáé åîÞãçóá óôïí ãéáôñü ôé óõìôþìáôá åß÷á êáé ìïõ Ýãñáøå Ýíá ÷áñôß ãéá íá ðáù íá äþóù áßìá.
¸äùóá áßìá êáé ìïõ åßðáíå óå ìéá åâäïìÜäá íá ðÜù íá ðÜñù ôá áðïôåëÝóìáôá áðü ôï íïóïêïìåßï Þ íá ôïõò ðÜñù ôçëÝöùíï.

ÐÝñáóå ìéá åâäïìÜäá êáé ðÞñá. Ìïõ åßðáíå äåí åßíáé Ýôïéìá ôá áðïôåëÝóìáôá áêüìá. Íá îáíáðÜñù óå Üëëç ìéá åâäïìÜäá. Ðåñßåñãï, äåí Ýäùóá üìùò ìåãÜëç óçìáóßá.
ÎáíáðÞñá êáé ìïõ åßðáíå üôé ðñÝðåé íá îáíáðÜù íá äþóù áßìá, åðåéäÞ ÷Üóáíå ôá áðïôåëÝóìáôá. ÐÜñá ðïëý ðåñßåñãï.
ÐÞãá êáé Ýäùóá ðÜëé áßìá êáé ïé íïóïêüìåò ìå êïéôÜãáíå ðåñßåñãá êáé Ýâáëáí ãÜíôéá üôáí ìïõ ðáßñíáíå ôï áßìá ôþñá.

¸öõãá áðü ôï íïóïêïìåßï êáé óôï äñüìï Üñ÷éóá íá óêÝöôïìáé ôé Ý÷ù êÜíåé ìå ðïéïí êëð. ÖïâÞèçêá ðïëý üôé ìðïñåß íá åßìáé ïñïèåôéêüò.
Êáé åãþ üðùò üëïé ìáò Ý÷ïõìå êÜíåé ôï ëÜèïò íá êÜíïõìå óåî ÷ùñßò êáðüôá Ýóôù êáé ìéá öïñÜ. ÁõôÞ ç öïñÜ ìïõ Ýêïøå ôï êåöÜëé.
ÔÝëïò ðÜíôùí, Þñèå ç óôéãìÞ íá ðÜñù ôá áðïôåëÝóìáôá êáé ìïõ åßðáíå íá ðÜù óôï íïóïêïìåßï.
¹ìïõíá óôçí ðüñôá ôïõ åñãáóôÞñéïõ êáé âãÞêå Ýíáò ãéáôñüò êáé ìïõ åßðå "Á,á åóý åßóáé ìå ôï ôÝôïéï, ðåñßìåíå Ýíá ëåðôü, Ýñ÷ïìáé" ÌðÞêå ìÝóá êáé ìéëïýóå ìå Ýíáí Üëëï ãéáôñü êáé åãþ ôïõò Ýâëåðá êáé Ýôñåìá ïëüêëçñïò.
¹ñèå ìå Ýíáí öÜêåëï óôï ÷Ýñé êáé ìïõ åßðå "ÐÜìå ìáæß óôïí ôñßôï üñïöï íá ìéëÞóåéò ìå Ýíáí ãéáôñü".
Ìïõ åäåéîå Ýíá ãñáöåßï êáé ìïõ åßðå "Ðåñßìåíå åäþ". Ðåñßìåíá Ýíá ôÝôáñôï. Åß÷á áëëÜîåé üëá ôá ÷ñþìáôá. Åß÷á ÷Üóåé ôç Ãç êÜôù áðü ôá ðüäéá ìïõ, Ýôñåìá, Ýêëáéãá, óêåöôüìïõíá äéÜöïñá êáé ðáñáêáëáãá ôï Èåü íá ìçí åßìáé ïñïèåôéêüò.
Ìå öþíáîáí êáé ìðÞêá ìÝóá ¸êáôóá óå ìéá êáñÝêëá Üøõ÷ïò, ìå âëÝììá ðáãùìÝíï.
Ï ãéáôñüò Üíïéîå ôï öÜêåëï ôï äéÜâáóå êáëÜ êáëÜ ìå êïßôáîå óôá ìÜôéá êáé ìïõ åßðå "äõóôõ÷þò åßíáé èåôéêü áãüñé ìïõ!"
Ôï ðåñßìåíá üôé èá ìïõ ðåé áõôü, üìùò äåí Þèåëá íá åßíáé áëÞèåéá!
Åêëáøá ðïëý. Äåí ìðïñïýóå íá ôï ÷ùíÝøåé ôï ìõáëü ìïõ üôé èá ìïõ óõìâåß óôá áëçèåéá.
ÌåôÜ ìïõ ìéëïýóå ãéá ôï ôé êáé ðùò êáé ðïõ ìïõ îáíáðÞñáíå áßìá ãéá ðåñéóóüôåñåò åîåôÜóåéò êáé Ýöõãá.

ÂãÞêá êáé ðÞñá ôïí êáëõôåñï ìïõ ößëï êáé Üñ÷éóá ôá êëÜììáôá. Äåí Þîåñá ôé íá ôïõ ðù, áðëÜ Ýêëáéãá óáí ìùñü.
Áõôüò êáôÜëáâå üôé Ý÷åé âãåé èåôéêü ôï test êáé ðñïóðáèïýóå íá ìå çñåìÞóåé. Ìïõ åßðå íá ðÜù óðßôé ôïõ íá ìéëÞóïõìå.
Ï äñüìïò áðü ôï íïóïêïìåßï ìÝ÷ñé ôï óðßôé ôïõ Þôáíå Üðåéñïò. Äåí ôåëåßùíå ðïôÝ.
¸öôáóá åêåß ìåôÜ áðü 6 þñåò. Åß÷á ðåñðáôÞóåé áðü âüñåéá ìÝ÷ñé íüôéá ÷ùñßò íá ôï êáôáëÜâù.
Åß÷áìå êÜôóåé óôï ìðáëêüíé ìðñïóôÜ óôç èÜëáóóá êáé ôïõ ìéëïýóá ãéá ôá áðïôåëÝóìáôá êëáßãïíôáò.
Áõôüò ðñïóðáèïýóå íá ìå çñåìÞóåé ìïõ Ýëåãå üôé õðÜñ÷ïõí öÜñìáêá êáé üôé äåí èá ðåèÜíù, êëð.
ÌåôÜ ìïõ åßðå üôé êáé ï ãêüìåíïò ôïõ åßíáé (+). ¸ðáèá óïê.
ÓÞìåñá ó÷åäüí Ýíá ÷ñüíï ìåôÜ óõíå÷ßæù íá æù ìå ôç óêÝøç üôé åßìáé ïñïèåôéêüò êáé üôé áõôü äåí èá áëëÜîåé ðïôÝ!
Äåí ìéóü ôïí Üíèñùðï ðïõ ìå êüëëçóå åðßôçäåò ç ìç, áðëÜ Ýðñåðå íá ìïõ ôï åß÷å ðåé.

Ãéá áõôü üëïé üóïé åßóôå êáé ôï îÝñåôå åßíáé êáëü íá ôï ëÝôå, ãéá íá ìçí ÷áëÜôå ôç æùÞ åíüò áíèñþðïõ ÷ùñßò íá öôáßåé ãéá êÜôé êáé ÷ùñßò íá èÝëåé ôï äùñÜêé ðïõ èá ôïõ ÷áñßæåôå. Åßíáé áìáñôßá!
Äåí îÝñù ôé Üëëï íá ðù. ÁðëÜ íá ðñïóÝîåôå ôé êÜíåôå êáé ìå ðïéïí êáé íá ìç ôï ìåôáäßäåôå óå ìéêñÜ ðáéäéÜ. Åßìáóôå áêüìá 21 ìüíï, ãéá íá ìáò ÷áëÜíå ôç æùÞ êÜðïéïé Üññùóôïé óôï ìõáëü. ÍôñïðÞ ôïõò ðïõ ôï êÜíïõí åðßôçäåò ãéá íá êïëëÞóïõí êáé ôïõò Üëëïõò.

ÐáéäéÜ íá óáò ðù ìéá éóôïñßá áðü ôï ðñïçãïýìåíï êáëïêáßñé.
Åßìáóôáí âñÜäõ óå ìéá gay ðáñáëßá êáé Þôáí Ýíáò ôýðïò, ôïí ïðïßï Þîåñá üôé åßíáé (+) êáé ôïí åßäá íá ãáìÜåé Ýíá ðéôóéñßêé ÷ùñßò êáðüôá.
ÐáéäéÜ ôïí Ýóðáóá ôï êåöÜëé ìå Ýíá ìðïêÜëé, äåí Üíôåîá.
Ðùò ìðïñïýí íá õðÜñ÷ïõí ôÝôïéïé Üíèñùðïé; Ôé ôïõ öôáåé ôï ðáéäß êáé ðñÝðåé íá ôïí êïëÞóåé?

×áéñåôþ ôïõò óõìðáèÝóôáôïõò ößëïõò ðïõ óôçñßæïõí ôï óÜéô áõôü!




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò